Amalgamated Bank Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Amalgamated Bank lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,738 shares of the medical research company’s stock after selling 958 shares during the quarter. Amalgamated Bank’s holdings in IQVIA were worth $6,630,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 62.3% in the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 15,392 shares of the medical research company’s stock valued at $3,025,000 after purchasing an additional 5,911 shares during the period. Edge Capital Group LLC lifted its holdings in shares of IQVIA by 622.7% in the 4th quarter. Edge Capital Group LLC now owns 13,096 shares of the medical research company’s stock valued at $2,573,000 after buying an additional 11,284 shares during the period. South Dakota Investment Council purchased a new stake in shares of IQVIA in the fourth quarter valued at approximately $2,462,000. Howard Capital Management Inc. grew its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares during the period. Finally, Abound Financial LLC purchased a new position in IQVIA in the fourth quarter worth $512,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Morgan Stanley increased their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Bank of America decreased their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.22.

Insider Activity

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.60% of the company’s stock.

IQVIA Price Performance

NYSE:IQV opened at $190.77 on Thursday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market cap of $33.59 billion, a price-to-earnings ratio of 25.44, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company’s 50-day moving average is $199.40 and its two-hundred day moving average is $215.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.